NCT03789682View on ClinicalTrials.gov

CD155 in Bladder Cancer

CompletedOBSERVATIONAL
Enrollment

151

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2025

Conditions
Bladder Cancer
Interventions
DRUG

Adjuvant chemotherapy

adjuvant chemotherapy using Gemcitabine plus Cisplatin

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03789682 - CD155 in Bladder Cancer | Biotech Hunter | Biotech Hunter